Skip to main content
SpringerLink
Log in

Clinical hold on tgAAC-94 trial lifted

  • News item
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. Targeted Genetics Corporation.Targeted Genetics Reports on Recombinant DNA Advisory Committee (RAC) Assessment of Its Phase I/II Trial of tgAAC94 for Inflammatory Arthritis. Media Release: 3 Dec 2007. Available from: URL: http://www.targetedgenetics.com

  2. Kaiser J.Questions remain on cause of death in arthritis trial. Science 317: 1665, No. 5845, 21 Sep 2007

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Clinical hold on tgAAC-94 trial lifted. React. Wkly. 1183, 4 (2008). https://doi.org/10.2165/00128415-200811830-00010

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128415-200811830-00010

Keywords

Search

Navigation